ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection

Life Sci Alliance. 2023 Jul 4;6(9):e202201880. doi: 10.26508/lsa.202201880. Print 2023 Sep.

Abstract

SARS-CoV-2 triggered the most severe pandemic of recent times. To enter into a host cell, SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2). However, subsequent studies indicated that other cell membrane receptors may act as virus-binding partners. Among these receptors, the epidermal growth factor receptor (EGFR) was hypothesized not only as a spike protein binder, but also to be activated in response to SARS-CoV-2. In our study, we aim at dissecting EGFR activation and its major downstream signaling pathway, the mitogen-activated signaling pathway (MAPK), in SARS-CoV-2 infection. Here, we demonstrate the activation of EGFR-MAPK signaling axis by the SARS-CoV-2 spike protein and we identify a yet unknown cross talk between ACE2 and EGFR that regulated ACE2 abundance and EGFR activation and subcellular localization, respectively. By inhibiting the EGFR-MAPK activation, we observe a reduced infection with either spike-pseudotyped particles or authentic SARS-CoV-2, thus indicating that EGFR serves as a cofactor and the activation of EGFR-MAPK contributes to SARS-CoV-2 infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme 2 / metabolism
  • COVID-19*
  • ErbB Receptors / metabolism
  • Humans
  • Peptidyl-Dipeptidase A / metabolism
  • SARS-CoV-2 / metabolism

Substances

  • spike protein, SARS-CoV-2
  • Angiotensin-Converting Enzyme 2
  • Peptidyl-Dipeptidase A
  • ErbB Receptors
  • EGFR protein, human